Ken Fisher acquired 415 Thousand Halozyme Therapeutics shares worth $27.3 Million. That's 0.01% of their equity portfolio (278th largest holding). The first Halozyme Therapeutics trade was made in Q2 2014. Since then Ken Fisher bought shares fourteen more times and sold shares on 23 occasions. The stake costed the investor $7.45 Million, netting the investor a gain of 267% so far.